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1. Abstract 1 
 2 
Background: Antimicrobial peptides (AMP) are widely recognized as promising 3 
alternatives to the current use of antibiotics and fungicides. Amino acid 4 
sequences of a vast majority of AMP share cationic and amphipathic 5 
biophysical properties that allow their insertion into lipid bilayers, and can lead 6 
to alteration of biological membrane functions. Initial characterization studies 7 
linked these properties to antimicrobial killing activity. However, additional data 8 
indicate that this is not the sole mode of action and that more subtle 9 
mechanisms might mediate the interaction with and effect to target microbes, as 10 
well as the specificity and toxicity of peptides. As such, antimicrobial peptides 11 
are increasingly viewed as powerful multifunctional drugs. 12 
 13 
Objective: This review will summarize findings on these alternative non-lytic 14 
modes of antimicrobial action that go beyond membrane disruption, with an 15 
emphasis on the specific interaction with microbial cell wall/membrane 16 
components, signaling of AMP exposure, and intracellular targets of peptide 17 
action. We will also explore how novel technologies can help to reveal, 18 
characterize and exploit these antimicrobial properties. 19 
 20 
Conclusion: Detailed knowledge on non-lytic modes of action of antimicrobial 21 
peptides will help in the design and discovery of novel antibacterial and 22 
antifungal compounds. 23 
 24 
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2. Introduction 1 
 2 
Antimicrobial peptides and/or small antimicrobial proteins (AMP) have been 3 
characterized from a vast number of organisms, from bacteria to insects, plants 4 
and humans [1]. The increasing problem of antibiotic resistance in clinic [2,3] 5 
and the pressure to reduce antibiotic and fungicide use in agricultural and food 6 
industry [4-7] has put AMP at the edge front as promising compounds to fight 7 
microbial infections and contaminations. Over 1000 natural AMP are currently 8 
known to their amino acid sequence. Moreover, the advent of amenable 9 
synthetic procedures, wide offer of biotech companies with peptide synthesis 10 
facilities, and high throughput (HT) approaches to synthesize and screen large 11 
collections and libraries of peptides have increased substantially the number 12 
and diversity of non-natural synthetic peptides with antimicrobial activity. Thus 13 
an enormous amount of peptides endowed with antimicrobial activity are 14 
currently known. However, only a minor proportion of them have been 15 
characterized in detail and studied in relation to their antimicrobial mode of 16 
action. 17 
 18 
AMP share common biophysical properties. They are small, from just 5-6 amino 19 
acid residues in some synthetic peptides to about 50 -and even up to 100- in 20 
natural ones; most of them (although not all) are cationic having positive charge 21 
at physiological conditions due to the presence of arginine and lysine residues, 22 
also have a high proportion (up to 50%) of hydrophobic residues, and are 23 
capable to fold or arrange into a variety of amphipathic structures and 24 
conformations. Cationic charge and amphipathic arrangement are on the basis 25 
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of their propensity of in vitro interaction with anionic lipid bilayers. In fact, initial 1 
studies after discovery of the first AMP were coincident in concluding that 2 
antimicrobial activity was a primary consequence of the capacity of cationic 3 
amphipathic peptides to interact and disrupt biological membranes, thus 4 
resulting in direct cell killing. Treatment of microorganisms with above minimal 5 
inhibitory AMP concentration resulted in microbial cell permeation that 6 
correlated with microbicidal potency. As consequence, many of the 7 
contributions that dealt with AMP mechanism relied on models of peptide 8 
interaction with -and disruption of- lipid bilayers. 9 
 10 
However, a key weakness point was that AMP cationic charge led to the early 11 
recognition that salts -at concentrations close to physiological- blocked AMP 12 
interaction with negatively charged microbe surface groups, and also 13 
diminished the in vitro inhibitory activity of microorganism growth. It was difficult 14 
to reconciliate this apparent limitation with the evidence that the high number 15 
and diversity of AMP in living organisms is indicative of an important 16 
physiological role, presumably in host defense. 17 
 18 
A way out of this dilemma derives from the recognition of multilayer roles of 19 
peptides in the regulation of host response, also acting on specific cells as 20 
effectors of the adaptive immune system [8]. Representative examples are 21 
human defensins and the cathelicidin LL-37 [9,10]. In particular, human 22 
defensins have emerged as an evolutionary link that bridges innate and 23 
adaptive immune responses [10]. But there are also additional alternatives to 24 
justify the prevalence of AMP in nature. 25 
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 1 
If specific AMP can participate in complex processes such as regulation of the 2 
mammal immune response, it is not senseless that can also exert multifaceted 3 
lethal actions on microbes. In fact, alternative mechanisms have been 4 
increasingly considered as part of AMP action against microbes [11-13]. 5 
Reports have analyzed peptide action towards microbes (not under in vitro 6 
membrane mimicking lipid environments) in greater detail, and accumulated 7 
convincing evidence that specific peptides do not exert antimicrobial activity by 8 
primarily permeabilizing cell membranes. Among these are apidaecin [14] or 9 
dermicidin [15] acting on bacterial cells, and specific human defensins and 10 
histatin-5 [16,17] or synthetic peptides [18,19] on fungal cells. Therefore, 11 
alternative non-lytic modes of action are recognized. Recent reviews have 12 
addressed this question in the case of antibacterial peptides [20,21] or the 13 
antifungal action of defensins [22]. This contribution aims to provide an updated 14 
and broader view to these alternative AMP modes of action or interactions with 15 
microbes, to the approaches to further investigate the extent and significance of 16 
these, as well as to discuss how this knowledge can be incorporated to the 17 
design of novel and improved AMP with higher antimicrobial potency and lower 18 
unspecific toxicity. The use of (model) microorganisms for which genomic-scale 19 
tools are available and the identification of genes that modulate the microbial 20 
susceptibility will be pivotal in the understanding of peptide antimicrobial action. 21 
We will not address, however, the responses of microbes to counteract peptide 22 
action, that recent reviews summarize in detail [23].  23 
 24 
3. Interaction with microbial surface. 25 
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 1 
Before reaching cell membranes, the first layer of contact for surrounding 2 
peptides is the outer microbial surface. There was no evidence of specific and 3 
canonical receptors linked to the interaction of peptides with target 4 
microorganism and microbial killing. Early reports on the similar activity of 5 
stereoisomeric AMP sustained the conclusion that interaction was not stereo-6 
specific [24]. Recently, non-chiral interaction has even been shown for peptides 7 
acting intracellularly [25]. However, there were also examples for which 8 
stereospecificity was shown [26], and in some cases correlated with an 9 
antimicrobial mechanism that was not pore-forming [14]. 10 
 11 
Several AMP bind bacterial lipopolysaccharide (LPS), and such binding is linked 12 
with the differential antimicrobial activity of peptide analogs with lower affinity for 13 
LPS [27,28] (Table 1). On the cell side, changes in cell wall/lipid bilayer 14 
composition can alter interaction and thus activity of peptides. A mechanism of 15 
bacterial resistance to peptide exposure involves the alteration of cell 16 
envelope/membrane, to increase the net charge thus reducing the electrostatic 17 
interaction with cationic antimicrobial peptides [23,29-31] (Table 2). More 18 
intriguingly, biophysical properties of specific synthetic peptides [32], or distinct 19 
combinations of temporins acting synergistically [33] can indeed modulate the 20 
translocation of peptides across bacterial outer envelopes and allow their 21 
access to and interaction with bacterial membranes.  22 
 23 
In addition to electrostatic attraction, specific cell membrane/wall components 24 
have been shown to promote the interaction with peptides. A significant 25 
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example is the antibacterial peptidic lantibiotic nisin, for which it is established 1 
that the membrane-bound peptidoglycan precursor Lipid II acts as a docking 2 
moiety to attract the peptide to the bacterial membrane and promote peptide 3 
insertion into membrane and cell permeation [34-36]. Interestingly, nisin is 4 
active at nanomolar range against bacteria containing Lipid II, roughly three 5 
orders of magnitude more active than peptides that only act through 6 
permeation. Nisin is not active against yeast or filamentous fungi; however, 7 
yeast spheroplasts are rapidly lysed when incubated in the presence of nisin at 8 
concentrations which do not affect intact cells [37]. This latter activity is 9 
presumed to be a consequence of the intrinsic capacity of nisin to disturb lipid 10 
bilayers. Thus, even in the case of true membrane-perturbing peptides, 11 
additional factors such as their propensity to interact with specific compounds 12 
might modulate (and enhance) their (membrane) activity. Interestingly, the 13 
related peptidic lantibiotic mersacidin also binds Lipid II, albeit at its terminal N-14 
acetylglucosamine, and  inhibits bacterial growth with no cell permeation 15 
[38,39]. Because of these binding capacities nisin, as well as mersacidin, also 16 
interfere with the peptidoglycan biosynthesis of bacterial envelope [35] (Table 17 
1), being one clear example of multilayer actions among AMP. 18 
 19 
Nisin is a well known example, but analogous situations may occur with specific 20 
defensins, whose antifungal activity is linked to the presence of distinct classes 21 
of membrane glycolipids. Hence, the activity of the plant defensin DmAMP1 and 22 
the cyclic lipopeptide syringomycin E are dependent on the biosynthesis of the 23 
acidic sphingolipid mannosyl diinositolphosphoryl ceramide, since the presence 24 
of functional IPT1 and SKN1 genes were linked to an enhanced resistance 25 
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phenotype of the yeast S. cerevisiae [40-42] (see Table 1 and Table 2). Also, 1 
the plant RsAFP2 or the insect heliomycin are coincident in requiring the 2 
presence of the neutral sphingolipid glucosyl ceramide [43,44]. The F. 3 
graminearum GCS1 gene involved in the biosynthesis of glucosyl ceramide also 4 
mediates the susceptibility to the plant MsDef1 defensin but, interestingly, not to 5 
the related MtDef4 [43]. It has been postulated that sphingolipid-rich lipid rafts 6 
could promote interaction with membranes of a subclass of defensin AMP [22]. 7 
However, other related defensins do not specifically require such membrane 8 
lipids, and in fact additional defensin-interacting molecules have been 9 
demonstrated [45]. On the other hand, plant PSD1 seems to operate through a 10 
distinct mechanism since it has been shown to be internalized and act on 11 
intracellular targets (see below) [46]. Therefore, although structurally related, 12 
the broad class of defensin peptides do comprise AMP with distinct interacting 13 
partners and effects on target cells.  14 
 15 
A repeated issue in several of these examples is that sugar moieties (mostly as 16 
part of more complex molecules) seem to act as interacting/docking partners for 17 
a variety of distinct AMP. In addition to the examples described above, 18 
phosphomannans of yeast cell wall mannoproteins increase toxicity of the 19 
antifungal osmotin, probably by serving also as docking structures that facilitate 20 
the interaction and diffusion across the cell wall [47] and numerous antifungal 21 
proteins are known for their ability to bind chitin [48,49]. Mutants of filamentous 22 
fungi with specific chitin synthase genes disrupted show alterations in their 23 
sensitivity to antifungal proteins [48] (Table 2). In this regard, specific cell wall 24 
components, including glycans and glycoproteins, have been recognized as 25 
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potential targets for selective antifungals [50-54]. It would be desirable the 1 
detailed characterization of the interaction of selected AMP with such glycan 2 
structures, in order to obtain information on both the potential microbial targets 3 
and the peptide structural requirements for activity. 4 
 5 
Additional studies report on the involvement of cell wall proteins on the fungal 6 
susceptibility to AMP. In several examples, the relevance of specific cell wall 7 
proteins is likely due to a general strengthening of cell wall that increases 8 
thickness or reinforces its structural resistance after exposure to peptides, as is 9 
the case of yeast PIR proteins in the interaction with tobacco osmotin [55] or 10 
other CWP proteins with nisin [37]. 11 
 12 
A remarkable example studied in detail is that of SSA1 and SSA2, cell surface 13 
proteins from Candida that mediate the activity of distinct AMP as human β-14 
defensins and histatin, but not of human neutrophil defensins [45,56]. These 15 
proteins are highly conserved in organism from distinct phylogenetic scale as 16 
part of the ATPase heat shock protein 70 (HSP70) family. In Saccharomyces, 17 
they have been localized to the nucleus, cytoplasm and cell wall, and are 18 
chaperones pivotal in active protein refolding as response to stress. Binding of 19 
histatin-5 to Candida cell wall SSA1/2 proteins was demonstrated and also 20 
linked to fungicidal activity [56,57]. This binding is necessary but not sufficient 21 
for the cell killing activity of the peptide [57], which also requires peptide cell 22 
internalization (see below). Histatin-5 binding has been recently mapped to the 23 
ATPase domain of SSA2 protein and showed to be enhanced by protein-bound 24 
nucleotides [58]. 25 
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 1 
Finally, there are peptides whose effect is expressed at the microbial 2 
surface/membrane but are known as non-lytic. The synthetic BM0 was identified 3 
as an inhibitor of the activity of a yeast plasma membrane ATPase (Pma1) that 4 
impairs in vitro growth with no permeation at growth-inhibitory concentrations 5 
[18]. The peptide locates and is reported to be active at the cell surface. 6 
 7 
4. Signaling of peptide exposure 8 
 9 
An antimicrobial action solely based on permeation is expected to be quick, not 10 
allowing a coordinated cell response to peptide exposure. However, a variety of 11 
different observations indicate that microorganism respond to antimicrobial 12 
peptides in different ways. For instance, transcriptome analyses have shown 13 
global changes in gene expression after exposure to distinct AMP in both 14 
bacteria [59-61] and fungi [62-64] (see below). These studies underline a 15 
response of microorganism that might be related to peptide mechanism of 16 
antimicrobial action and/or be part of the mechanisms to counteract peptide 17 
deleterious effect. In any case, some of these reports also indicate the 18 
existence of cell signaling components that coordinate such responses. 19 
 20 
In bacteria, two-component and related sensor systems participate in AMP 21 
recognition and induction of transduction cascades that modulate the bacterial 22 
response to peptide exposure [59,65]. The two-component system PhoPQ is a 23 
determinant of virulence in a number of Gram-negative bacteria and mediates 24 
the interaction with AMP [30,66,67], and the membrane bound sensor kinase 25 
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PhoQ is activated by cationic AMP binding to an acidic surface domain [65]. 1 
The additional PmrAB two-component system also responds and mediates the 2 
response and resistance to AMP [61,68,69]. An analogous three-component 3 
system could operate in Gram-positives and is involved in the signaling and 4 
coordinated expression of different responses to AMP [59]. These sensor 5 
systems are part of the bacterial defensive armor and a general response 6 
mediated by them is the modification of the anionic charge of the bacterial 7 
surface to reduce peptide interaction (see below). Therefore, they would not be 8 
directly linked with the killing mechanism of AMP. However, the detailed 9 
knowledge of their involvement in the response to peptides and the structural 10 
characterization of the interaction could lead to the design of AMP capable of 11 
by-passing or disturbing these bacterial surveillance systems. 12 
 13 
In yeast, a transmembrane receptor-like protein is required for sensitivity to 14 
osmotin, and functions upstream of RAS2 in a signaling pathway that induces 15 
apoptosis after exposure to the AMP [70,71]. Different fungal protein kinase 16 
signaling cascades mediate the response to distinct antimicrobial peptides and 17 
proteins, and mutations in the corresponding genes resulted in increased 18 
sensitivity [63,72,73] (Table 2). At least in some examples, the involvement of 19 
each pathway seems to be dependent of the specific peptide as was nicely 20 
demonstrated in the case of two related plant defensins [73]. The increased 21 
sensitivity of fungal cells deleted in components of these signaling cascades is 22 
indicative that they are part of the microbial response to peptide exposure and 23 
damage, and not necessarily linked to the peptide antimicrobial action. 24 
 25 
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On the other hand, independent studies indicate that specific AMP (such as frog 1 
dermaseptins, human lactoferrin, tobacco osmotin or fungal AFP) induce 2 
apoptosis markers in yeast [71,74,75] or filamentous fungi [76]. Contrary to the 3 
above discussed data, mutation of involved genes enhance resistance to 4 
peptides, which supports that induced microbial suicide is indeed part of the 5 
fungal killer mechanism in these examples [71,74,76]. Reactive oxygen species 6 
(ROS) are known as markers of cell suicide [77], and additional studies broaden 7 
the number of AMP for which their effect is associated with intracellular ROS 8 
production, which also suggest an induction of intracellular signaling pathways 9 
[71,78,79]. However, the role of ROS in antimicrobial action remains 10 
controversial for specific peptides such as histatin [80,81]. 11 
 12 
5. Cell internalization 13 
 14 
Distinct AMP have been demonstrated to translocate across the cell membrane 15 
in a non-disruptive mechanism, and examples exist in bacteria and fungi. Insect 16 
apidaecin was one of the first AMP for which a non-pore forming mechanism 17 
was invoked [14], and early uptake assays with radiolabeled peptide indicated 18 
retention by E. coli cells [82]. The use of fluorescently labeled peptides and 19 
proteins coupled to confocal microscopy has boosted the demonstration of cell 20 
internalization of this and other AMP [19,46,83-89]. Additional techniques such 21 
as immunodetection were used to show that antimicrobial proteins enter fungal 22 
hyphae [87]. In several of these reports, peptide internalization was shown at 23 
peptide concentrations and/or times of exposure at which no obvious growth 24 
alteration or cell membrane damage could be observed. For instance, the 25 
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synthetic hexapeptide PAF26 was internalized at sub-inhibitory concentrations 1 
by fungal hyphae and caused severe morphological alterations in the absence 2 
of mycelium permeation, which was finally produced at higher completely 3 
inhibitory concentrations [19]. Another noteworthy example is that of the 4 
synthetic NK-2 peptide, which is selectively internalized by Plasmodium infected 5 
red blood cells due to the increase in the negative charge of the membrane that 6 
occurs in infected cells, and subsequently kills the protozoan pathogen 7 
intracellulary [90]. 8 
 9 
Targeting of peptides to specific cell compartments has also been shown and in 10 
some cases linked to the antimicrobial activity. Thus, the pea defensin PSD1 11 
was shown to locate inside the nucleus of the model fungus Neurospora crassa, 12 
wherein it might alter cell cycle progression [46]. Also, histatin-5 at low (inactive) 13 
concentrations is directed towards yeast vacuoles, while inhibitory higher 14 
concentrations locate in the cytosol [17].  15 
 16 
A paradigmatic example of cell penetration is that of antimicrobial peptides 17 
derived from bovine lactoferrin, which have been shown to be internalized by 18 
both bacterial and yeast cells [86,91]. It remains to be determined, however, 19 
whether cell internalization share common mechanism for both classes of 20 
microorganisms. 21 
 22 
The capability to penetrate target cells is therefore increasingly viewed as a 23 
common property of distinct cationic AMP (Table 1). AMP having cell 24 
translocation activity share biophysical properties with the so-called cell 25 
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penetrating peptides (CPP), which has brought into question the differences 1 
between antimicrobial and cell penetrating peptides [92]. CPP have been 2 
proposed as shuttle vehicles for the delivery of killing or therapeutical molecules 3 
into (mammalian) cells [93]. Peptides initially known as CPP onto mammalian 4 
cells have been later demonstrated to have antimicrobial effects on distinct 5 
microorganisms, and this activity correlated with internalization into microbial 6 
cells [94,95]. An attractive hypothesis is therefore that this class of peptides are 7 
in fact dual molecules in which internalization determinants do not necessarily 8 
overlap with antimicrobial [21]. Interestingly, for selected AMP such as the 9 
proline-rich apidaecin the microbial internalization and killing activities seem to 10 
be separated, and peptide uptake was necessary but not sufficient for 11 
antibacterial activity of selected analogs [82]. Experiments should address the 12 
identification of these (separate) determinants in additional model AMP, in order 13 
to determine the minimum amino acid sequence requirements for these 14 
activities, if any, and help in the design of “modular” domains with distinct 15 
functional capabilities. 16 
 17 
An still unsolved question relates to the actual mechanism(s) of non-lytic 18 
peptide internalization [96,97]. Despite numerous efforts, the underlying 19 
mechanism of AMP/CPP uptake is still unclear and controversy exists, which 20 
likely reflects the involvement of distinct pathways and processes depending on 21 
the peptide and cells under study. Several peptides have been demonstrated to 22 
be internalized in an active, energy-dependent process [82,88]. Internalization 23 
may follow multiple and simultaneous endocytic pathways, and even at high 24 
peptide concentrations a non-lytic endocytosis-independent uptake [97]. Initial 25 
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interaction seems to depend on cell surface complex glycans [98]. Deciphering 1 
the mechanism of peptide cell penetration including the related 2 
similarities/differences among CPP acting on mammalian cells and AMP on 3 
microbes, will undoubtedly help to design improved antimicrobial peptides 4 
endowed with higher specificity. 5 
 6 
AMP sequence analogs will surely help to characterize the above described 7 
open questions such as the internalization mechanism/pathways, and 8 
determine structure activity relationships [84]. An study showed the importance 9 
of a single proline residue at the hinge region of buforin, required for bacterial 10 
membrane translocation [83]. This residue is also critical for maintaining both 11 
antibacterial and antifungal activities of the peptide. Interestingly, buforin 12 
analogs with the proline substituted did not penetrate bacterial cells but rather 13 
remained at the surface and seemed to kill bacteria through permeation.  14 
 15 
6. Intracellular targets 16 
 17 
It is expected that AMP that translocate into cells might disturb cell homeostasis 18 
in different ways determined by their intrinsic properties as well as their 19 
targeting/interaction with cellular organelles. Due to their cationic nature, most 20 
AMP readily bind nucleic acids (DNA and RNA) in vitro which might result in a 21 
broad inhibition of DNA synthesis, transcription and/or mRNA translation inside 22 
cells [82,85,99-101]. Even for some peptides known to cause permeation, an 23 
inhibition of DNA, RNA and/or protein synthesis was reported [102,103], 24 
indicating that disruption of cell membranes might be combined with inhibition of 25 
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intracellular targets. However, it is obvious for nearly all the examples analyzed, 1 
that nucleic acid binding by known AMP is quite unspecific, at least in vitro. 2 
Therefore, specificity of inhibition of such peptides would be derived from the 3 
interaction with outer microbial envelopes or cell membrane components that 4 
enable internalization. 5 
 6 
More specific intracellular mechanisms have also been proposed. Distinct 7 
approaches have been used to identify host protein partners of AMP. Affinity 8 
purifications identified S. cerevisiae DNA binding proteins involved in DNA 9 
repair, as partners of the AMP dermaseptin S3 [74], and contributed to the 10 
understanding that its mode of action is related to the induction of apoptosis in 11 
yeast. Similarly, immunoaffinity purification of proline-rich AMP incubated with 12 
E. coli proteins identified the DnaK and GroEL bacterial chaperones with the 13 
ability to bind AMP, and DnaK binding was shown to be related to bacterial 14 
killing [104,105] (Table 1). DnaK is an ATPase HSP that is similar to the class of 15 
SSA proteins from yeast that bind to histatin (see above), and in fact the AMP 16 
pyrrhocoricin binding inhibits ATPase activity and protein refolding by the 17 
chaperone, which would led to accumulation of misfolded proteins and lethality 18 
[104]. DnaK and related chaperones are also overexpressed in Lactococcus 19 
lactis strains with enhanced resistance to nisin [106]. These chaperones are 20 
biologically selected for recognition and binding of aberrantly folded 21 
proteins/peptides, and as such are critical for the cell response and survival to 22 
various types of stress (for instance, heat stress). Therefore, it seems that 23 
distinct classes of AMP are prone to interact with specific cell chaperones. It 24 
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remains to be determined whether this is a behavior that extends to other AMP, 1 
and how this is related to cell killing. 2 
 3 
A unique example of intracellular target is that of the pea defensin PSD1, which 4 
in a yeast two hybrid approach interacted with several fungal nuclear proteins, 5 
including cyclin F with which also in vitro binding was demonstrated [46]. The 6 
defensin translocated to the fungal nucleus (see above) and further analysis 7 
indicated that affects normal cell cycle progression. 8 
 9 
Several members of the mammalian superfamily A of RNases have been 10 
shown to have a direct antimicrobial function, and be involved in the innate 11 
immune system [107]. Plant antimicrobial PR-10 proteins also have 12 
ribonuclease-like properties. The peanut RNase AhPR-10 has been shown to 13 
locate inside hyphae and kill susceptible fungi [108]. Interestingly, a point 14 
mutation devoid of RNase activity internalizes into hyphae but does not inhibit 15 
fungal growth or disrupt membrane permeability, thus separating the cell 16 
penetration from the ribonuclease activity and, further, linking this and the 17 
antimicrobial properties. Although not related with nuclease activity, there are 18 
previous examples in which cell penetration has been separated from peptide 19 
antimicrobial activity [82], thus confirming that penetration and killing can be 20 
separated steps of the antimicrobial mechanism of peptides. 21 
 22 
Also, there are examples of AMP that are not internalized although elicit an 23 
intracellular action, as specific plant defensins that induce extended 24 
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citosqueleton disorganization despite being retained at the cell surface of yeast 1 
cells [72]. 2 
 3 
7. Genome-wide analyses of microbial response to peptide exposure. 4 
 5 
The use of genomic tools is expected to help in the characterization of 6 
alternative modes of AMP action, including the effects on microorganisms, the 7 
determinants of susceptibility to peptide action and the identification of potential 8 
microbial targets. These approaches will lead to the identification of microbial 9 
genes that modulate sensitivity to peptides (Table 2), as a critical part of the 10 
detailed knowledge of AMP action. However, few studies have been reported 11 
yet, so as to draw general conclusions. Most of these have been conducted by 12 
exposing model organisms such as E. coli or S. cerevisiae to sub-lethal peptide 13 
concentrations, and analyzing the transcriptomic response or testing the 14 
susceptibility of genome-wide mutant collections. An alternative approach is to 15 
compare the transcriptional profile of AMP-resistant bacterial strains with that of 16 
the corresponding parentals [106]. 17 
 18 
These types of studies have been carried out both in Gram-negative (i.e., E. 19 
coli) and Gram-positive bacteria [59-61,106]. A major transcriptional change 20 
relates to stress response, and also to the attempt to reduce peptide interaction 21 
and exposure, namely by increasing the net charge of the bacterial surface 22 
(explained above), strengthening of exopolysaccharide envelope, and inducing 23 
extrusion/transporter systems [59,61,106,109]. Interestingly, it was found that 24 
selected E. coli genes respond differently to distinct AMP as occurs with the 25 
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sensor BasS of the AMP responsive two-component BasRS [61] (see also 1 
above), reflecting a specificity in AMP sensing and/or action that would depend 2 
on the peptide sequence. This latter work also showed that non-active 3 
sequence analogs do not exert the same transcriptional response as the 4 
parental antimicrobial peptide. In any case, it is noteworthy that most of the 5 
genes that respond significantly to AMP correspond to proteins of unknown 6 
function [60,61], implying the existence of a part of the microbial response that 7 
clearly needs to be characterized in detail and might be related to the 8 
activity/specificity of the peptides. 9 
 10 
There is also a limited number of reports on the analysis at a genome scale of 11 
the effect of AMP on fungi, and these have been focused on unicellular yeasts 12 
[62-64]. Conclusions need to be critically tested for their relevance to 13 
filamentous fungi. For instance, a common report in yeast is the induction by 14 
distinct AMP of the osmotic stress response regulated by the HOG MAPK 15 
pathway, involved in osmotic tolerance and cell wall maintenance [62,63]. 16 
Indeed, it seems to be a cross-tolerance phenotype between AMP and osmotic 17 
stress [62]. However, the HOG pathway does not participate in the response of 18 
F. graminearum to specific defensins [73]. 19 
 20 
A direct comparison of a S. cerevisiae genome-wide screen between two 21 
unrelated AMP that had been previously known to kill by permeation -a 22 
dermaseptin derivative and magainin 2- indicate that their actions are more 23 
complex than membrane disruption, and also demonstrated common and -24 
interestingly- unique effects of each peptide [64]. Thus, treatment with either 25 
21 of 41 
peptide elicits responses related to DNA damage that would be part of a 1 
general reaction to damage/stress. Likewise, a significant functional annotation 2 
related with ribosome assembly and rRNA processing was found among genes 3 
repressed by both peptides. However, and considering changes in gene 4 
expression and alterations of susceptibility of deletant strains, only a minor 5 
proportion of the nearly 5,000 genes analysed showed common behaviours 6 
among the two peptides. For instance, no gene deletions were found that 7 
conferred increased resistance to both peptides. Deletion of genes involved in 8 
vacuolar transport and protein targeting to the vacuole increased sensitivity to 9 
the dermaseptin peptide [64]. An independent work showed that over-10 
expression of a different vacuolar H+-ATPase increased resistance to a distinct 11 
AMP [110], and targeting of histatin-5 to vacuoles from the surrounding 12 
cytoplasm seems to be a survival mechanism in Candida [17]. Thus, different 13 
approaches that include genomic screens identified transport to fungal vacuoles 14 
as a common mechanism of defence to AMP. 15 
 16 
Also, comparisons among genomic screens based on collections of mutant 17 
strains or on transcriptomic data indicate that both approaches are 18 
complementary and required for a deep characterization of AMP mechanisms, 19 
since they do not necessarily led to the identification of the same gene sets [64]. 20 
An additional approach is also the screening of cDNA expression libraries to 21 
identify genes whose over-expression can influence the sensitivity of fungi to 22 
AMP [110], which permitted the identification of genes that led to increased 23 
either resistance or susceptibility to a plant defence peptide. Authors report that 24 
these would have not been identified in deletant mutant screens since the 25 
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corresponding knockout strains did not show alterations of sensitivity to 1 
peptides. 2 
 3 
A limitation of the above studies on fungi is that they use unicellular yeasts, 4 
namely S. cerevisiae. Although it has obvious advantages, S. cerevisiae is also 5 
limited as a model organism. AMP active against laboratory yeast strains may 6 
have no effect on pathogenic yeast or filamentous fungi and viceversa. Also, S. 7 
cerevisiae has undergone gene duplication during evolution that may produce 8 
function redundancy and bias the analysis of peptide antifungal activity. Despite 9 
these disadvantages, the use of yeast as model for drug (antimicrobial peptide) 10 
characterization and development has a wide potential, albeit similar studies 11 
should be extended/confirmed onto filamentous fungi and must be encouraged. 12 
 13 
A significant conclusion in all these genome-wide studies with both bacteria and 14 
fungi is that genes involved in known resistances to nowadays antibiotics and 15 
fungicides are not usually identified, indicating that AMP are indeed compounds 16 
of novel modes of action that could aid in the development of novel 17 
antimicrobial strategies. 18 
 19 
8. Expert opinion 20 
 21 
Researchers have agreed over the last years that non-lytic modes of AMP 22 
action exist, and even co-exist with membrane disrupting properties of well 23 
known lytic peptides [11,20-22]. In our view such alternative mechanisms go 24 
beyond membrane interaction and in a broad sense might explain the specific 25 
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properties of selected peptides, including their specificity towards certain 1 
microbes or cells and also their potency not always correlated with their 2 
membrane permeation capacity. As summary, Figure 1 shows a conceptual 3 
model of the steps of AMP action onto microbes that includes, but also goes 4 
beyond, their interaction with biological membranes. Three major steps are 5 
envisioned as relevant to accommodate the current knowledge of AMP 6 
mechanisms in a general model of peptide antimicrobial action: (1) Interaction 7 
with outer microbial structures, (2) interaction with cell membrane that can result 8 
in peptide sensing that signals peptide exposure, internalization/translocation to 9 
cell interior, and/or disruption of lipid bilayer, and (3) intracellular targets that are 10 
related to/explain peptide activity. In this review we have discussed examples 11 
on how specific the activity of selected peptides can be, regarding all these 12 
steps. Previously not foreseen examples are the significance of stress-related 13 
chaperones observed with distinct microorganisms and peptides at the level of 14 
protein:peptide interactions [57,58,105], inhibition of activity [104], and 15 
responsive genes [106]. Also, the importance of vacuolar transport and peptide 16 
targeting to the vacuole as suggested by overexpression/deletion of related 17 
genes [64,110], and localization data [17]. Detailed knowledge of the molecular 18 
and cellular bases of each one of these steps in an increasing number of 19 
peptides/microbes (including clinical and agronomically relevant pathogens) 20 
might allow the design of AMP with increased potency and lower unspecific 21 
toxicity. 22 
 23 
In our view, studies on antimicrobial peptide action must be shifted from the 24 
peptide structural requirements/biophysical properties to the cell determinants 25 
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of sensitivity to peptides. The use of model organisms, genomic approaches, 1 
and screening/selection of collections of mutants will be pivotal to unravel the 2 
mechanism of action of selected peptides. We have given some relevant 3 
examples of this [61,64,106], but they are still scarce. These types of studies 4 
are identifying relevant genes modulating sensitivity to AMP (Table 2). With an 5 
increasing number of reports we will be in good position to ask the fundamental 6 
question on whether there are non-lytic modes of AMP action “common” to 7 
distinct peptides and whether each peptide class has specific properties not 8 
shared by others. Also related, we will be able to classify AMP in relation to their 9 
effect on target cells, as well as to identify those cell targets that are more 10 
promising in terms of potency and specificity. 11 
 12 
The use of synthetic peptides and their sequence analogs will be critical in 13 
establishing structure/activity relationships between peptide sequence, 14 
antimicrobial activity and effects on microorganisms, with the potential for 15 
extrapolation to the genetic/molecular determinants of peptide susceptibility of 16 
the latter. It is intriguing, for instance, that highly related plant defensins seem to 17 
interact with distinct cell components/signaling cascades [43,73]. A 18 
consequence is that minor amino acid changes in AMP could be responsible for 19 
differences in the specific modes of action [35,57]. Due to their small size and 20 
feasibility of synthetic production, small AMP can be used to dissect the 21 
molecular basis of such differences and specificities. 22 
 23 
It is conceivable that an holistic combination of detailed knowledge of modes of 24 
action, genome screens, high-throughput peptide identification technologies, 25 
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and amino acid sequence requirements, could lead to the development of novel 1 
rationally designed AMP to be used as drugs against functionally important 2 
microbial targets. 3 
 4 
Among the very interesting potential of AMP, the elucidation of specific modes 5 
of action constrained in relatively small peptide molecules might allow the 6 
combination of more than one killing mechanisms in one single AMP, as 7 
multitarget drugs, and could potentiate the antimicrobial activity while 8 
diminishing the probability of developing resistance in the susceptible microbes 9 
[35]. 10 
 11 
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Figure Legend 1 
 2 
Figure 1.  3 
General model of the antimicrobial mechanism of AMP. The figure shows a 4 
schematic view of an eukaryotic cell, although the conceptual framework can be 5 
also applied to bacterial cells. A major difference would rely on peptide import to 6 
nucleus, which has been demonstrated for specific AMP in fungal cells (see text 7 
for details). Three major steps are depicted in the antimicrobial mechanism of 8 
AMP (blue line): (1) Interaction with outer microbial structures, (2) interaction 9 
with cell membrane components that results in disruption of lipid bilayer/pore-10 
formation (2a), internalization/translocation to cell interior (2b), and/or signaling 11 
of peptide exposure (2c); and (3) intracellular targets (as detailed, 3a-3d) that 12 
have been demonstrated in distinct examples as related to peptide activity (see 13 
text for details). The relevance of glycan structures for peptide interaction is 14 
highlighted by hexagons within cell wall/envelope glycans, membrane lipids, 15 
and glycoproteins. AMP folding (thick blue line) may change upon each step.  16 
 17 
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Table 1. Selected examples of non-lytic antimicrobial peptide mechanisms 
Peptide Microorganism Interaction/Binding Cell Uptake Mechanism References 
Nisin Bacteria Lipid II  Inhibition of peptidoglycan synthesis [35,36] 
Buforin II Bacteria  Yes Binding DNA/RNA [83,85] 
Magainin 2 Bacteria LPS Yes  [91,111] 
Indolicidin Bacteria LPS Yes Binding to nucleic acids/Inhibition of proteins and nucleic acid synthesis [99,112] 
Pyrrhocoricin Bacteria  Yes HSP (DnaK) binding / Prevention of chaperone protein folding [84,104] 
Lactoferricin B Bacteria LPS Yes Binding to nucleic acids / Inhibition of macromolecular synthesis [28,91,113] 
DmAMP1 Fungi/yeast M(IP)2C sphingolipid   [42] 
RsAFP2 Fungi/yeast GlcCer sphingolipid  ROS [79] 
Psd1  Fungi  Yes Binding to Cyclin F / Cell cycle impairment [46] 
Osmotin PR5 Yeast Membrane Receptors / Phosphomannoproteins  Apoptosis [47,70] 
BM0 Yeast  No Inhibition of Plasma membrane H+-ATPase [18] 
Dermaseptin S3 Yeast   Apoptosis, ROS and DNA damage [74] 
Histatin-5 Yeast SSA1/2 proteins Yes ROS (¿?), Subcellular targeting [17,58,80] 
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Table 2. Representative examples of genes that modulate the sensitivity of microorganisms to antimicrobial peptides. 
Peptide Microorganism Genes Functional annotation/category References 
Different AMP S. typhimurium pagP Lipid A acylation [30] 
Different AMP S. aureus Dlt Operon D-alanine esterification of LTA [29] 
Different AMP S. aureus MprF Lys modification of PG [31] 
Nisin L. lactis DltD D-alanine esterification of LTA [106] 
  AhrC Transcriptional repressor of Arc operon (Arginine catabolism) [106] 
Protamine S. meliloti ExoT, ExoU, NdvB Exopolysaccharide and glucan biosynthesis [109] 
  Y01361, HutU, UreF Nitrogen metabolism [109] 
  Y01826 ABC membrane transporter [109] 
DmAMP1 S. cerevisiae IPT1 Sphingolipid biosynthesis [42] 
  SKN1 Sphingolipid biosynthesis [40] 
Syringomicyn E S. cerevisiae IPT1, ELO2, ELO3, CSG1, CSG2 Sphingolipid biosynthesis [41] 
MiAMP1 S. cerevisiae YGL191W Mitochondrial Cyt. c ox. sub. [110] 
  VMA11 Vacuolar H+-ATPase sub. c [110] 
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  SKS1 Serine/Threonine protein kinase [110] 
  PTC7 Protein phosphatase type 2C [110] 
Dermaseptin S3  S. cerevisiae Izh2, Izh3, Stm1, Aif1 Regulation of Apoptosis [74] 
MsDef1 F. graminearum GCS1 Glucosylceramide synthase [43] 
MsDef1 / MtDef2 
/ RsAFP2 F. graminearum STE11, STE7, GPMK1, MGV1 MAPK signaling cascade [73] 
AFP A. oryzae ChsB, CsmA Chitin synthases, classes III and V [48] 
AFP F. oxysporum ChsV Chitin synthase, class V [48] 
 1 
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